Б.Оюунцацрал
Loading...
Товч нэр
Б.Оюунцацрал
Бүтэн нэр
Батсайхан Оюунцацрал
Латин нэр
Batsaikhan Oyuntsatsral
Албан тушаал
Ахлах багш
Харьяалал
ORCID
19 results
Now showing 1 - 10 of 19
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, "Атопийн дерматитийн эмнэлзүйн хүндийн зэргийн үнэлгээний аргуудыг харьцуулан судалсан нь"(2023-06); ;М.Батлхагва ;Б.Жавзандулам ;У.Номин-ЭрдэнэЭ.Мөнхжин - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The study of allergen protein of the mare’s milk, fermented mare’s milk and mugwort.(2015); ;Gantulga B ;Narantsetseg LMunkhbayarlakh S - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Амьсгалын замын харшилтай ба харшилгүй хүүхдийн цусан дахь CD14-ийн түвшинг харьцуулсан нь(2021-04); ;С.Мөнхбаярлах ;Н.Төвшинтөр ;Л.НаранцэцэгБ.Баяр-Өлзий - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Арьс судлалын хичээлийн шалгалтын сорилд дүн шинжилгээ хийсэн нь(2022-04); ;Э.Мөнхжин ;М.Батлхагва ;У.Номин-эрдэнэБ.Жавзандулам - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Хүнд зэргийн хөрзөнт хайрст үлд өвчнийг секукинумабаар эмчилсэн нь(2023-03-22); ;Б.ХандсүрэнХ.Энхжин - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The first diagnosed case of Steroid induced Kaposi’s sarcoma in Mongolia.(2016) ;Khandsuren B ;Ariunaa M ;Undram S - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Therapeutic mode of action of Methotrexate(Mongolian National University of Medical Sciences, 2016); ;Dashlkhumbe B ;Enkhtur Ya ;Nandintsetseg BChimedtseren BObjectives: Methotrexate (MTX) has been used in clinical practice for over a half-century and its action mechanism is believed to rely on the direct inhibition of DNA synthesis leading to suppression of cell proliferation. However, its anti-inflammatory action mechanism is not fully explained. In some autoimmune or overactive immune-related diseases such as psoriasis, it has been demonstrated that interleukin (IL)-23/IL-17/lL-22 pathway plays a key role in disease pathogenesis. In this study, we aimed to investigate the suppressive action of MTX on the IL[1]23/1 L-17/1 L-22 pathway in psoriasis. Methods: We made a model of psoriasis on mice using imiquimod (IMQ). The mice were divided into three groups: disease-free control group and disease-induced groups with no treatment and MTX-treatment. Clinical, histological and immunological parameters were evaluated among the groups. Results: Treatment with MTX decreased the psoriatic skin changes and the histological alterations induced by IMQ. MTX exerted its treatment effects via inhibition of the main players in the pathogenetic axis, the IL-23, IL-17A, F and IL-22, that were found to be increased in the diseased mice. Regulatory T cells expressing CTLA4 or GITR or PD1 molecules on their surface were not related to these decrements. Conclusion: The therapeutic action mechanism of MTX is related to the direct inhibition of the IL-23/1 L-17/1 L-22 pathway, but not the induction of inhibitory molecules or expansion of regulatory T cells. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Хүүхдэд дюрингийн дерматит өвчнийг шууд дархан туяарах аргааг оношилсон тохиолдол(2023-04); ; ; ;Javzandulam Bat-OrshikhMunkhjin Enkhsaikhan
